Protocol Ledger

NCT06514612 · Phase III · RECRUITING

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

Interventional Phase III clinical trial protocol NCT06514612 sponsored by Santen SAS in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-30 Enrollment: 234 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06514612
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)234 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06514612
Protocol FieldVerified Registry Value
NCT IdentifierNCT06514612
Consolidated Lead SponsorSanten SAS
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment234 participants (ESTIMATED)
Registered Start Date2024-12-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06514612
Hospital Research SiteLocationSite Profile
Hospital Universitario Virgen de las NievesGranada, SpainOpen Hospital Dossier ->
Hospital Universitario Ramón y CajalMadrid, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI